Eosinophil–lymphocyte interactions in the tumor microenvironment and cancer immunotherapy

Sharon Grisaru-Tal, Marc E. Rothenberg, Ariel Munitz*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Eosinophils are important effector cells and therapeutic targets in allergic diseases. Emerging data indicate that eosinophils infiltrate a variety of solid tumor types and have pleiotropic activities by at least two non-mutually exclusive mechanisms: direct interactions with tumor cells, and intricate cross-talk with lymphocytes. In light of the immune checkpoint inhibition revolution in cancer therapy, we review eosinophil–lymphocyte interactions in the tumor microenvironment. We also analyze potential interactions between eosinophils and lymphocyte subsets, including T cells, natural killer cells and innate lymphoid cells. We provide perspectives on the consequences of these interactions and how eosinophils are accessory cells that can affect the response to various forms of T cell-mediated immunotherapies and might be therapeutically targeted to improve cancer immunotherapy.

Original languageEnglish
JournalNature Immunology
StatePublished - Sep 2022


FundersFunder number
Azrieli Foundation Canada-Israel
Cancer Biology Research Center
Dotan Hemato Oncology fund
Richard Eimert Research Fund on Solid Tumors
Sunshine Charitable Foundation
US-Israel bi-national science foundation2015163
National Institutes of HealthR37 AI045898, P30 DK078392, R01 AI124355
National Institute of Allergy and Infectious DiseasesU19AI070235
Israel Cancer Research Fund
Israel Cancer Association
Israel Science Foundation886/15, 542/20
Tel Aviv University


    Dive into the research topics of 'Eosinophil–lymphocyte interactions in the tumor microenvironment and cancer immunotherapy'. Together they form a unique fingerprint.

    Cite this